Clinical Trials Browser

Phase 3 × infigratinib × Gastrointestinal × Clear all

NCT03773302 2024-05-08

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Phase 3 Terminated

48 enrolled 26 charts

Gastrointestinal

Cholangiocarcinoma